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WTPs. For a WTP of $270,000, the P(CE) for the no screen option was .482 with the 
TRI distributions and .535 with our revised distributions. ConClusions: In this 
case, despite the criticism of triangular distributions generally, CEA results were 
not appreciably different qualitatively or quantitatively with the change to more 
accepted distributional assumptions. For an intervention with an ICER closer to 
the CE threshold, the importance may be greater.
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objeCtives: In CP-CML, there are few therapeutic options for highly-resistant 
patients (e.g. third line [3L] or beyond), who have a poor prognosis. Current treat-
ment options are tyrosine kinase inhibitors (TKIs) and allogeneic stem cell trans-
plantation (allo-SCT) for suitable patients. Efficacy of ponatinib, designed to inhibit 
the kinase activity of native BCR-ABL and all mutant variants, including T315I, was 
demonstrated in patients with highly-resistant CML in the pivotal phase II Ponatinib 
Ph+ ALL and CML Evaluation(PACE) trial. In the absence of head-to-head trials, an 
economic model employing a Swedish public healthcare perspective was developed 
to assess the cost-effectiveness of ponatinib for 3L treatment of CP-CML compared 
with current treatment options in Sweden. Methods: The cost-effectiveness 
model compares ponatinib, second-generation TKIs (dasatinib, nilotinib, bosutinib), 
and allo-SCT, with cost per life-years (LY) saved and cost per quality-adjusted life-
years (QALYs) gained as outcome measures, and a lifetime time horizon. Resource 
use includes study drugs, monitoring and follow-up, adverse events and allo-SCT 
procedure. Costs, based on current tariffs in Sweden, and benefits (LY and QALYs) 
projected based on 12-month treatment response, were discounted at 3%/year. 
We performed sensitivity analyses (SA) to identify parameters that most strongly 
influenced results. Clinical validity was evaluated by comparing model-generated 
survival estimates with relevant clinical data. Results: Over the patients’ life-
time, ponatinib provides an increase in LY of almost 7 years and a gain of almost 
4 QALYs compared with the next-best therapy, bosutinib. The incremental cost-
effectiveness ratios range from SEK78,044/QALY gained vs. allo-SCT to SEK351,702/
QALY gained vs. bosutinib. SA showed the model was robust to plausible changes 
in input parameters and had good face validity. ConClusions: This analysis sug-
gests that treating 3L CP-CML with ponatinib provides substantial clinical benefit 
as compared with current alternatives at a reasonable cost, from the perspective 
of the Swedish public healthcare system.
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objeCtives: Biologics are used for the treatment of inflammatory bowel diseases 
(IBDs), Crohn´s disease (CD) and Ulcerative colitis (UC), while their costs are signifi-
cant high. To allocate health spending efficiently, biologics for IBDs are an important 
target for cost-effectiveness analyses. The aim of this study was to systemically 
review the cost-effectiveness of biologics for IBDs and to evaluate the methodo-
logical quality of cost-effectiveness analyses. Methods: The literature search 
was performed to Medline (Ovid), Cochrane Library and SCOPUS in June 2014. The 
cost-utility analyses of biologics for IBDs in adults were included in the review. 
Biologics were compared with conventional medical treatment, another biologic 
treatment, placebo and surgery. Data extraction form was designed beforehand. 
All costs were converted to 2014 euro. The methodological quality of the included 
studies was assessed by Drummond´s checklist, Philips´ checklist and Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) guideline. Results: 
Of the 1828 references found in the literature search, 25 studies were included in 
the final review. The main causes affected the cost-effectiveness of the biologics 
are the activity of the disease, the duration of the biological treatment and the 
treatment strategy. Among patients refractory to conventional medical treatment 
(CMT) for IBD, incremental cost-effectiveness ratio (ICER) ranged from dominance 
to € 549,335 per Quality-Adjusted Life Year (QALY) compared with CMT. Adalimumab 
produced more frequently lower ICERs than infliximab in comparison with CMT 
for CD. When compared biologics with another biologic treatment for CD, ICER 
ranged from dominance to € 24,012,483/QALY. A study including both direct and 
indirect costs produced more favorable ICERs than studies including only direct 
costs. ConClusions: With a threshold of € 35,000/QALY, current evidence showed 
that biologics are cost-effective for the induction treatment of active and severe 
IBD. Biologics were not cost-effective for moderate IBD. Between biologics the cost-
effectiveness remains unclear.
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objeCtives: A cost-effectiveness analysis (CEA) has been performed, from an 
Italian public payer perspective, to compare the first advanced therapy medici-
nal product (ATMP) containing stem cells for the treatment of Limbal Stem Cell 
Deficiency (LSCD) with conservative treatment, a standard alternative pathway. 
LSCD is a rare condition characterized by the shortage of limbal stem cells in the 
eye resulting in corneal conjunctivalization, corneal opacity, visual impairment and 
even blindness. A medicinal product has been recently approved by EMA as the first 
treatment in moderate-severe LSCD due to chemical or physical burn. Methods: 
Efficacy data derive from a retrospective, case-series, non-randomized, non-con-
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objeCtives: Adults with Philadelphia chromosome-positive (Ph+) acute lympho-
blastic leukaemia (ALL) who develop resistance or intolerance to first- and second-
generation tyrosine-kinase inhibitors (TKIs) may be eligible for potentially curative 
allogeneic hematopoietic stem cell transplantation (alloHSCT) if remission of the 
disease is achieved. The third-generation TKI ponatinib has been shown to be safe 
and efficacious in TKI resistant and intolerant patients, with 47% achieving a major 
cytogenetic response (MCyR). Accordingly, ponatinib followed by alloHSCT in those 
who achieve MCyR represents a potential therapeutic alternative to best supportive 
care (BSC) with standard chemotherapy only. Methods: A Markov cohort model 
was constructed to assess the cost-effectiveness after dasatinib failure of ponatinib 
followed by alloHSCT in patients who achieve MCyR, versus BSC. Direct medical 
costs for ponatinib, BSC, alloHSCT, monitoring and follow-up, and adverse events 
were considered from the perspective of the UK National Health Service. Treatment 
outcomes were estimated from data for the Ph+ ALL patients in a phase 2 ponatinib 
trial (PACE), alloHSCT recipients in the LALA-94 trial, and a historical cohort receiv-
ing BSC. In the absence of valuations for Ph+ ALL health states, utilities for blast-
phase chronic myeloid leukaemia were used. Outcomes were evaluated in terms 
of life-years (LY) and quality-adjusted life-years (QALYs), and cost-effectiveness 
in terms of life-years gained (LYG) and QALYs gained. Results: Patients in the 
ponatinib plus alloHSCT arm had higher overall survival (4.14 versus 0.32 LY) and 
QALYs (2.57 versus 0.09) than BSC, at an increased cost (£88,553 versus £21,208). 
Incremental cost-effectiveness ratios were £17,700/LYG and £27,200/QALY gained 
relative to BSC. ConClusions: Given the assumptions and limitation of this 
analysis, our results suggest ponatinib may offer improved survival and health-
related quality-of-life by enabling patients with Ph+ ALL who have failed dasatinib 
to achieve remission and benefit from alloHSCT, at a moderate increase in cost 
compared with BSC.
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objeCtives: To assess the cost-effectiveness of romiplostim as treatment for 
adult ITP splenectomized patients with refractory disease or non-splenectomized 
patients with surgery contra-indication, in comparison with the use of Intravenous 
Immunoglobulin (IVIg) rescue therapy only, from the Brazilian private health 
care perspective. Methods: A cost per response model was developed. Overall 
response rates were derived from the romiplostim clinical trials (Kuter 2008) and 
were weighted by the proportion of patients splenectomized or not. The use of IVIg 
as rescue therapy in both arms was derived from Pullarkat, 2009. Treatment cost 
was calculated assuming drug wastage for an average patient weight of 72.4Kg and 
height of 170cm. Bleeding rates according to severity and site (gastrointestinal, 
intracranial and other) were estimated for patients without response considering 
data from Weitz, 2012. Resources and procedures used for the treatment of bleed-
ing events were based on a medical specialist group recommendation and costs 
were obtained from official Brazilian databases. Gynecological bleed was used as 
a proxy for costs of other inpatient bleeds. The analysis assumed 50% splenecto-
mized patients and was performed over a time horizon of 24 weeks. Results: The 
average cost per patient over 24 weeks was R$60,509 for romiplostim (including 
rescue therapy and bleeding events costs) and R$173,319 for IVIg. 83.2% and 7.1% 
of patients in the romiplostim and IVIg arm respectively achieved overall response, 
leading to a cost per response equal to R$72,727 for romiplostim compared with 
R$2,424,047 for IVIg as rescue therapy. ConClusions: The use of romiplostim in 
the treatment of ITP increases and maintains the platelet level of splenectomized 
and non-splenectomized patients and, at the same time, reduces the need of 
rescue therapy as IVIg. That generates cost savings and positions romiplostim as 
a dominant (less costly and more effective) strategy when compared with IVIg 
rescue therapy only.
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objeCtives: In 2009 Yoo and Grosse (Y/G) compared screening/no screening for 
CAH in a CEA, including a PSA using triangular distributions with minimum (MIN), 
mode and maximum (MAX) values for parameters. These distributions have been 
criticized for use in PSAs (Briggs et al). This research reproduces the Y/G analysis 
and then conducts a PSA with more appropriate distributional assumptions to 
evaluate potential bias from triangular distributions. Methods: We limited our 
reanalysis to a change in distributions to focus on the question of distributional 
sensitivity. For parameters in Y/G with symmetric triangular distributions (MIN 
and MAX values equidistant from their mean/mode), we used a normal distribu-
tion with the same mean and chose a Standard Error based on a 95% confidence 
interval defined by the MIN and MAX values of the triangular. For non-symmetric 
distributions, we fit a beta distribution to the triangular, keeping the means equal 
and ensuring that the tails of the distributions extended slightly beyond the MIN 
and MAX of the triangular. Results: We reproduced the Y/G deterministic ICER 
($292,841 vs. Y/G reported $292,000). We also reproduced the triangular distribu-
tion-based PSA ICER from Y/G (256,947 vs Y/G $255,700). In our revised PSA, our 
mean ICER was higher ($273,187), but the CEACs were nearly superimposable. For 
low Willingness to Pay (WTP) values, the probability of being cost-effective - P(CE) 
- was very similar between the two analyses. There was some divergence at higher 
